ReviewJournal of translational medicine2017

The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?

Loukman Omarjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.